Related Experiment Video
Updated: Apr 29, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor,
Insights
Sevelamer did not reduce microbial translocation or inflammation in HIV patients. However, it lowered LDL cholesterol and soluble tissue factor, suggesting potential cardiovascular benefits.
Area of Science:
- Cardiovascular Disease Research
- HIV/AIDS Research
- Inflammation Studies
Background:
- Abnormal inflammation is linked to cardiovascular disease and mortality in HIV patients.
- Sevelamer, a phosphate binder, may reduce inflammation by decreasing microbial translocation.
- Clinical trial NCT 01543958 investigated sevelamer's effects in HIV-infected individuals.
Purpose of the Study:
- To evaluate the impact of sevelamer therapy on microbial translocation, inflammation, and cardiovascular markers in HIV-infected patients not on antiretroviral therapy.
Main Methods:
- A single-arm study involving 36 HIV-infected subjects.
- 8 weeks of sevelamer treatment.
- Assessment of microbial translocation, inflammation, T-cell activation, soluble tissue factor, LDL cholesterol, oxidized LDL cholesterol, and D-dimer levels.
Main Results:
- Sevelamer did not significantly alter markers of microbial translocation, inflammation, or T-cell activation.
- Significant decreases were observed in soluble tissue factor, LDL cholesterol, and oxidized LDL cholesterol levels.
- D-dimer levels showed a significant increase during sevelamer treatment.
Conclusions:
- Sevelamer therapy did not reduce microbial translocation in this HIV-infected population.
- The observed reductions in LDL cholesterol and soluble tissue factor suggest potential cardiovascular benefits.
- Further research is warranted to explore sevelamer's role in managing cardiovascular risk in HIV patients.
Unlabelled:
Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits.
Clinical Trials Registration:
NCT 01543958.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...

